In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu®) and active metabolite

European Journal of Pharmacology

Volumn 628, Issue 1-3, 2010, Pages 6-10

  Lindemann, Lothar ^a   Jacobsen, Helmut ^a   Schuhbauer, Diana ^a   Knoflach, Frederic ^a   Gatti, Silvia ^a   Wettstein, Joseph G ^a   Loetscher, Hansruedi ^a   Chu, Tom ^b   Ebeling, Martin ^a   Paulson, James C ^c   Prinssen, Eric ^a   Brockhaus, Manfred ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE BIOSCIENCE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Influenza; Neuraminidase; Neuropsychiatric adverse event; Oseltamivir; Selectivity; Tamiflu

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; DRUG METABOLITE; OSELTAMIVIR; RECOMBINANT ENZYME; SIALIDASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN TISSUE; CHO CELL; COGNITION; CONTROLLED STUDY; DRUG SELECTIVITY; ENZYME ASSAY; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; MOOD; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RODENT;

ANIMALS; ANTIVIRAL AGENTS; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; NEURAMINIDASE; OSELTAMIVIR; PHOSPHATES; PRIMATES; PRODRUGS; RATS; SUBSTRATE SPECIFICITY;

EID: 73649083999     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.11.020     Document Type: Article

References (18)

1. Blumentals W.A., and Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. Med. Gen. Med. 9 (2007) 23
2. Goshima N., Nakano T., Nagao M., and Ihara T. A clinical study of abnormal behaviors in patients with influenza. Infect. Immun. Child. 18 (2006) 371-376
3. Hata K., Koseki K., Yamaguchi K., Moriya S., Suzuki Y., Yingsakmongkon S., Hirai G., Sodeoka M., von Itzstein M., and Miyagi T. Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrob. Agents Chemother. 52 10 (2008) 3484-3491
4. He G., Massarella J., and Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37 (1999) 471-484
5. Lew W., Chen X., and Kim C.U. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 7 (2000) 663-672
6. Li C.Y., Yu Q., Ye Z.Q., Sun Y., He Q., Li X.M., Zhang W., Luo J., Gu X., Zheng X., and Wei L. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Res. 17 (2007) 357-362
7. Mendel D.B., Tai C.Y., Escarpe P.A., Li W., Sidwell R.W., Huffman J.H., Sweet C., Jakeman K.J., Merson J., Lacy S.A., Lew W., Williams M.A., Zhang L., Chen M.S., Bischofberger N., and Kim C.U. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42 (1998) 640-646
8. Monti E., Preti A., Venerando B., and Borsani G. Recent development in mammalian sialidase molecular biology. Neurochem. Res. 27 (2002) 649-663
9. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353 (2005) 1363-1373
10. Okumura A., Kubota T., Kato T., and Morishima T. Oseltamivir and delirious behavior in children with influenza. Pediatr. Infect. Dis. J. 25 (2006) 572
11. Oxford J. Oseltamivir in the management of influenza. Expert Opin. Pharmacother. 6 (2005) 2493-2500
12. Potier M., Mameli L., Belisle M., Dallaire L., and Melancon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-d-N-acetylneuraminate) substrate. Anal. Biochem. 94 (1979) 287-296
13. Satoh K., Nonaka R., Ogata A., Nakae D., and Uehara S. Effects of oseltamivir phosphate (Tamiflu) and its metabolite (GS4071) on monoamine neurotransmission in the rat brain. Biol. Pharm. Bull. 30 (2007) 1816-1818
14. Schentag J.J., Hill G., Chu T., and Rayner C.R. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J. Clin. Pharmacol. 47 (2007) 689-696
15. Sieghart W., and Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr. Top. Med. Chem. 2 (2002) 795-816
16. Toovey S., Rayner C.R., Prinssen E., Chu T., Donner B., Dutkowski R., Sacks S., Solsky J., Small I., and Reddy D. Post-marketing safety assessment of neuropsychiatric adverse event risk in patients with influenza treated with oseltamivir. X International Symposium on Respiratory Viral Infections Singapore, 28th February-2nd March, Abstract (2008)
17. Whiting P.J. The GABAA receptor gene family: new opportunities for drug development. Curr. Opin. Drug Discov. Dev. 6 (2003) 648-657
18. Wilcox M., and Zhu S. Oseltamivir therapy appears not to affect the incidence of neuropsychiatric adverse events in influenza patients. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, 17-20 September 2007 (2007) (poster 114)